DHR vs. INCY: Danaher vs. Incyte Stock Comparison
How do Danaher (DHR) and Incyte (INCY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Danaher (DHR) and Incyte (INCY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but DHR is classified in Life Sciences Tools & Services while INCY is classified in Biotechnology.
| Profile Item | DHR | INCY |
|---|---|---|
| Name | Danaher Corp. | Incyte Corp. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Biotechnology |
| GICS Sub-Industry | Life Sciences Tools & Services | Biotechnology |
| Market Capitalization | 161.86 billion USD | 24.39 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | December 29, 1978 | November 4, 1993 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | DHR | INCY |
|---|---|---|
| Total Return (1Y) | 11.88% | 14.06% |
| Total Return (3Y, Annualized) | 6.67% | 32.03% |
| Total Return (5Y, Annualized) | -2.05% | 12.69% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | DHR | INCY |
|---|---|---|
| Volatility (1Y, Annualized) | 30.61% | 33.19% |
| Beta (5Y) | 0.76 | 0.78 |
| Max Drawdown (5Y) | -43.31% | -40.50% |
| Avg. Volume (3M) | 3.94M | 1.58M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | DHR | INCY |
|---|---|---|
| Sharpe Ratio (1Y) | 0.25 | 0.29 |
| Sortino Ratio (1Y) | 0.35 | 0.46 |
Profitability
ROE (TTM)
Both Danaher (DHR) at 8.19% and Incyte (INCY) at 7.84% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.19%
- Max
- 109.18%
- DHR
- 8.19%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.84%
- Max
- 109.18%
- INCY
- 7.84%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
For every dollar of sales, both Danaher (DHR) at 16.91% and Incyte (INCY) at 6.71% retain more as net profit than most peers, landing in the top net margin quartile of their industries.
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.91%
- Max
- 18.05%
- DHR
- 16.91%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.71%
- Max
- 18.05%
- INCY
- 6.71%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Danaher (DHR) at 21.13% and Incyte (INCY) at 33.72% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.13%
- Max
- 83.12%
- DHR
- 21.13%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
33.72%
- Max
- 83.12%
- INCY
- 33.72%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | DHR | INCY |
|---|---|---|
| ROE (TTM) | 8.19% | 7.84% |
| ROA (TTM) | 4.06% | 17.78% |
| Net Margin (TTM) | 16.91% | 6.71% |
| Operating Margin (TTM) | 21.13% | 33.72% |
| Gross Margin (TTM) | 59.36% | 56.02% |
Growth
Revenue Growth
Both Danaher (DHR) at 2.90% and Incyte (INCY) at 21.22% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Incyte (INCY) at 4,173.33% clears its industry range for EPS growth, a much stronger earnings trajectory than Danaher (DHR) at -4.54%, which is closer to a typical peer reading.
Growth Metrics
| Metric | DHR | INCY |
|---|---|---|
| Revenue Growth (YoY) | 2.90% | 21.22% |
| Revenue Growth (3Y CAGR) | -2.67% | 14.84% |
| EPS Growth (YoY) | -4.54% | 4,173.33% |
| EPS Growth (3Y CAGR) | -19.44% | 61.56% |
Financial Strength
Current Ratio (MRQ)
Incyte (INCY) at 3.84 keeps current ratio within its industry’s typical mid-range, while Danaher (DHR) at 1.63 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for DHR.
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.63
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- DHR
- 1.63
- Min
- 0.10
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.84
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- INCY
- 3.84
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Incyte (INCY) at 0.01 keeps leverage in the lower industry quartile, while Danaher (DHR) at 0.52 runs a more typical debt-to-equity mix.
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.52
- Max
- 1.42
- Q3
- 0.65
- DHR
- 0.52
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.01
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- INCY
- 0.01
- Min
- 0.00
Financial Strength Metrics
| Metric | DHR | INCY |
|---|---|---|
| Current Ratio (MRQ) | 1.63 | 3.84 |
| Debt / Equity (MRQ) | 0.52 | 0.01 |
| Net Debt / EBITDA | 2.68 | -1.88 |
Dividends
Dividend Yield (TTM)
Incyte (INCY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Danaher (DHR) reports a yield of 0.67%, ranking against industry peers normally.
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.67%
- DHR
- 0.67%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- INCY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Incyte (INCY) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Danaher (DHR) reports a payout of 25.17%, ranking against industry peers normally.
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.17%
- DHR
- 25.17%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- INCY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | DHR | INCY |
|---|---|---|
| Dividend Yield (TTM) | 0.67% | 0.00% |
| Dividend Payout Ratio (TTM) | 25.17% | 0.00% |
Valuation
P/E Ratio (TTM)
Danaher (DHR) at 38.12 is near its industry’s usual P/E ratio, while Incyte (INCY) at 61.05 sits in the richer quartile — INCY needs stronger growth or earnings quality to justify the premium.
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
38.12
- Max
- 85.34
- Q3
- 43.46
- DHR
- 38.12
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
61.05
- Max
- 85.34
- INCY
- 61.05
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Danaher (DHR) at 6.32 and Incyte (INCY) at 4.06 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.32
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- DHR
- 6.32
- Q1
- 3.01
- Min
- 0.01
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.06
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- INCY
- 4.06
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Danaher (DHR) at 3.02 and Incyte (INCY) at 4.33 are valued close to their industries’ norm against book — neither stands out from peers.
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.02
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- DHR
- 3.02
- Q1
- 1.69
- Min
- -5.59
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.33
- Max
- 13.53
- Q3
- 6.54
- INCY
- 4.33
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | DHR | INCY |
|---|---|---|
| P/E Ratio (TTM) | 38.12 | 61.05 |
| P/S Ratio (TTM) | 6.32 | 4.06 |
| P/B Ratio (MRQ) | 3.02 | 4.33 |
| Free Cash Flow Yield (TTM) | 2.93% | 5.28% |